Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

The pharmaceutical giant will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S.

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

Officials with Merck Biopharmaceutical Company broke ground on a new, 470,000 square foot biologics center at the Chestnut ...

Portugal's Galp will be gradually restarting units at its Sines oil refinery over the coming days after the major Iberian ...

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...